亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

濟南誠匯雙達化工有限公司銷售公司  

各類原料藥及其中間體

搜索
新聞中心
  • 暫無新聞
產品分類
  • 暫無分類
聯系方式
  • 聯系人:黃先生
  • 電話:0531-58897087
  • 傳真:0531-58897093
  • QQ:1135136112
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 利奈唑胺 原料藥價格生產廠家CAS
利奈唑胺 原料藥價格生產廠家CAS
單價 面議對比
詢價 暫無
發貨 山東濟南市付款后3天內
過期 長期有效
更新 2017-04-05 15:50
 
詳細信息
 利奈唑胺  原料藥價格生產廠家CAS

英文名:Linezolid

化學名稱:(S)-N-{[3-(3-氟4-(4-嗎啉基>苯)2-氧-5 唑啉]甲基}-乙酰胺

含量:99%

CAS:165800-03-3

分子式:C16H20FN3O4

分子量:337.35

質量標準:企業標準

外觀:白色粉末

包裝:10kg/紙板桶

用途:解熱鎮痛原料藥

1.0000pt;" >用途:氨基酸類腸外營養劑.

 

:Arial;color:rgb(68,68,68);letter-spacing:0.0000pt;font-weight:normal;text-transform:none;font-style:normal;font-size:9.5000pt;" >

 

包裝規格:25公斤/桶

用途:抗癌新藥S-1組成成分之一,可抑制抗腫瘤藥物替加氟的毒負作用

©2025 濟南誠匯雙達化工有限公司銷售公司 版權所有   技術支持:化工網   訪問量:6532  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |